Replies to post #443680 on Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

LOL...they paid $14B because of the cap already pretty high to begin with...

[JoeBear906]

Boi oh boi, no a buyout similar to KARTX-BMO, lets say AVXL-Biogen. KARTX traded for about 200/share for a year and is to be bought for 330/share Yippee. If AVXL sold similarly, the one year average of $9/share and a purchase price of $15/share. Hardly a bonanza. Sigma 1 receptor agonist platform is worth vastly more than that.

[Bourbon_on_my_cornflakes]

BARELY ADEQUATE: In Anavex terms, a $14B buyout would be ~ $150 per share.

That would be the amount barely adequate for the years of risk and frustration. I would not feel good until we hit $250 at least. That would be a fair amount for alz and Rett, but nothing else. If we really have got it and can get approved for multiples diseases like PD, autism, seizures, schizophrenia, cardio, glaucoma, then obviously the $1249 number sounds about right.